<!DOCTYPE html>
<html lang="en-US"><head>
		<meta charset="UTF-8">
		<title>FT931-15476</title>
	</head>
	<body>
		<main>
			<p>930113 FT  13 JAN 93 / International Company News: Hafslund wins FDA approval HAFSLUND NYCOMED, the Norwegian pharmaceuticals group best-known for x-ray imaging products, has received approval from the US Food and Drug Administration for a new product used in magnetic resonance imaging of the central nervous system. Hafslund A shares yesterday closed up NKr5 at NKr146 and B shares rose NKr7 to NKr159. The FDA approval represents a breakthrough for Hafsland's Omniscan, which it described as the second most important product developed by the group. Hafslund said Omniscan would provide continued revenue growth.</p>
		</main>
</body></html>
            